Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index

• DOI: 10.1371/journal.pone.0211337
• Publication Date: 2019-01-31T18:35:00Z
• Authors: Laura L. Michel; Laura Sommer; Rosa González Silos; Justo Lorenzo Ber...; Alexandra von Au; Julia Seitz; André Hennigs; Katharina Smetanay; Michael Golatta; Jörg Heil; Florian Schütz; Christof Sohn; Andreas Schneeweiss; Frederik Marmé
• Keywords: Adult; Science; Breast Neoplasms; Kaplan-Meier Estimate; Mastectomy, Segmental; Young Adult; 03 medical and health sciences; 0302 clinical medicine; Humans; Prospective Studies; Neoplasm Metastasis; Early Detection of Cancer; Mastectomy; Aged; Q; R; Middle Aged; Prognosis; Survival Analysis; Neoadjuvant Therapy; 3. Good health; Chemotherapy, Adjuvant; Medicine; Female; Neoplasm Recurrence, Local; Research Article

Locoregional recurrence after neoadjuvant chemotherapy for primary breast cancer is associated with poor prognosis. It is essential to identify patients at high risk of locoregional recurrence who may benefit from extended local therapy. Here, we examined the prediction accuracy and clinical applicability of the MD Anderson Prognostic Index (MDAPI).Prospective clinical data from 456 patients treated between 2003 and 2011 was analyzed. The Kaplan-Meier method was used to examine the probabilities of locoregional recurrence, local recurrence and distant metastases according to individual prognosis score, stratified by type of surgery (breast conserving therapy or mastectomy). The possible confounding of the relationship between recurrence risk and MDAPI by established risk factors was accounted for in multiple survival regression models. To define the clinical utility of the MDAPI we analyzed its performance to predict locoregional recurrence censoring patients with prior or simultaneous distant metastases.Mastectomized patients (42% of the patients) presented with more advanced tumor stage, lower tumor grade, hormone-receptor positive disease and consequently lower pathological complete response rates. Only a few patients presented with high-risk scores (2,7% MDAPI≥3). All patients with high-risk MDAPI score (MDAPI ≥3) who developed locoregional recurrence were simultaneously affected by distant metastases.Our data do not support a clinical utility of the MDAPI to guide local therapy.